Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alecensa and Avastin in Advanced ALK-Positive NSCLC
NCT02521051Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2015
- Primary completion
- Apr 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of alectinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Recommended Phase II Dose of Alectinib at 21 days, Recommended Phase II Dose of Bevacizumab at 21 days and 1 more. Started Sep 2015; status: terminated.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02521051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02521051.